Why Morphic Holding Stock Is Skyrocketing Today

Prosper Junior Bakiny, The Motley Fool
·2 min read
Why Morphic Holding Stock Is Skyrocketing Today

More important than its financial results, the biopharmaceutical company announced results from a clinical trial and other developments regarding collaboration agreements with big-name drugmakers. Morphic Holding reported interim data from a phase 1 clinical trial for MORF-057, a potential medicine for inflammatory bowel disease (IBD).